PortalPublikationenClinical practice recommendations on lipoprotein apheresis f...

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia

Standard

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia : an expert consensus statement from ERKNet and ESPN. / Reijman, M Doortje; Kusters, D Meeike; Groothoff, Jaap W; Arbeiter, Klaus; Dann, Eldad J; de Boer, Lotte M; de Ferranti, Sarah D; Gallo, Antonio; Greber-Platzer, Susanne; Hartz, Jacob; Hudgins, Lisa C; Ibarretxe, Daiana; Kayikcioglu, Meral; Klingel, Reinhard; Kolovou, Genovefa D; Oh, Jun; Planken, R Nils; Stefanutti, Claudia; Taylan, Christina; Wiegman, Albert; Schmitt, Claus Peter.

in: medRxiv, 15.11.2023.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Preprint › Forschung

Harvard

Reijman, MD, Kusters, DM, Groothoff, JW, Arbeiter, K, Dann, EJ, de Boer, LM, de Ferranti, SD, Gallo, A, Greber-Platzer, S, Hartz, J, Hudgins, LC, Ibarretxe, D, Kayikcioglu, M, Klingel, R, Kolovou, GD, Oh, J, Planken, RN, Stefanutti, C, Taylan, C, Wiegman, A & Schmitt, CP 2023, 'Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN', medRxiv. https://doi.org/10.1101/2023.11.14.23298547

APA

Reijman, M. D., Kusters, D. M., Groothoff, J. W., Arbeiter, K., Dann, E. J., de Boer, L. M., de Ferranti, S. D., Gallo, A., Greber-Platzer, S., Hartz, J., Hudgins, L. C., Ibarretxe, D., Kayikcioglu, M., Klingel, R., Kolovou, G. D., Oh, J., Planken, R. N., Stefanutti, C., Taylan, C., ... Schmitt, C. P. (2023). Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN. medRxiv. https://doi.org/10.1101/2023.11.14.23298547

Vancouver

Reijman MD, Kusters DM, Groothoff JW, Arbeiter K, Dann EJ, de Boer LM et al. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN. medRxiv. 2023 Nov 15. https://doi.org/10.1101/2023.11.14.23298547

Bibtex

@article{72ae2928b4ab4d729a2d61d656aabea6,
title = "Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN",
abstract = "Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is well established since three decades, lowering serum LDL-C levels by more than 70% per session. Data on the use of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia mainly consists of case-reports and case-series, precluding strong evidence-based guidelines. We present a consensus statement on lipoprotein apheresis in children based on the current available evidence and opinions from experts in lipoprotein apheresis from over the world. It comprises practical statements regarding the indication, methods, treatment targets and follow-up of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia and on the role of lipoprotein(a) and liver transplantation.",
author = "Reijman, {M Doortje} and Kusters, {D Meeike} and Groothoff, {Jaap W} and Klaus Arbeiter and Dann, {Eldad J} and {de Boer}, {Lotte M} and {de Ferranti}, {Sarah D} and Antonio Gallo and Susanne Greber-Platzer and Jacob Hartz and Hudgins, {Lisa C} and Daiana Ibarretxe and Meral Kayikcioglu and Reinhard Klingel and Kolovou, {Genovefa D} and Jun Oh and Planken, {R Nils} and Claudia Stefanutti and Christina Taylan and Albert Wiegman and Schmitt, {Claus Peter}",
year = "2023",
month = nov,
day = "15",
doi = "10.1101/2023.11.14.23298547",
language = "English",
journal = "medRxiv",

}

RIS

TY - JOUR

T1 - Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia

T2 - an expert consensus statement from ERKNet and ESPN

AU - Reijman, M Doortje

AU - Kusters, D Meeike

AU - Groothoff, Jaap W

AU - Arbeiter, Klaus

AU - Dann, Eldad J

AU - de Boer, Lotte M

AU - de Ferranti, Sarah D

AU - Gallo, Antonio

AU - Greber-Platzer, Susanne

AU - Hartz, Jacob

AU - Hudgins, Lisa C

AU - Ibarretxe, Daiana

AU - Kayikcioglu, Meral

AU - Klingel, Reinhard

AU - Kolovou, Genovefa D

AU - Oh, Jun

AU - Planken, R Nils

AU - Stefanutti, Claudia

AU - Taylan, Christina

AU - Wiegman, Albert

AU - Schmitt, Claus Peter

PY - 2023/11/15

Y1 - 2023/11/15

N2 - Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is well established since three decades, lowering serum LDL-C levels by more than 70% per session. Data on the use of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia mainly consists of case-reports and case-series, precluding strong evidence-based guidelines. We present a consensus statement on lipoprotein apheresis in children based on the current available evidence and opinions from experts in lipoprotein apheresis from over the world. It comprises practical statements regarding the indication, methods, treatment targets and follow-up of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia and on the role of lipoprotein(a) and liver transplantation.

AB - Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is well established since three decades, lowering serum LDL-C levels by more than 70% per session. Data on the use of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia mainly consists of case-reports and case-series, precluding strong evidence-based guidelines. We present a consensus statement on lipoprotein apheresis in children based on the current available evidence and opinions from experts in lipoprotein apheresis from over the world. It comprises practical statements regarding the indication, methods, treatment targets and follow-up of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia and on the role of lipoprotein(a) and liver transplantation.

U2 - 10.1101/2023.11.14.23298547

DO - 10.1101/2023.11.14.23298547

M3 - Preprint

C2 - 38014132

JO - medRxiv

JF - medRxiv

ER -